Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907387 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00907387 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT00907387, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults and duration of effect.
Interventions
- OTHER Placebo
- DRUG RT001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00907387
The ClinicalTrials.gov registry entry for NCT00907387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00907387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00907387 about?
NCT00907387 is a clinical study titled "Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines". The purpose of this study is to evaluate the safety and efficacy of RT001 to treat moderate to severe lateral canthal lines in adults and duration of effect.
What is the current status of trial NCT00907387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2009-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00907387?
The interventions under investigation include: Placebo (OTHER), RT001 (DRUG).
Who is sponsoring clinical trial NCT00907387?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.